NCT07154901View on ClinicalTrials.gov

A Phase I Study to Investigate the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

December 26, 2025

Study Completion Date

December 26, 2025

Conditions
Renal Impairment
Interventions
DRUG

Opemalirsen (AZD2373)

Single, subcutaneous injection of AZD2373

Trial Locations (2)

32808

RECRUITING

Research Site, Orlando

33172

RECRUITING

Research Site, Miami

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY